NICE Recommends Boston Scientific CRT-D Devices Powered By EnduraLife™ Battery Technology For Treatment Of Heart Failure

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

March 16, 2020

NICE, (National Institute for Health and Care Excellence) issued medical technology guidance recommending the use of Boston Scientific Corporation cardiac resynchronization therapy defibrillators (CRT-D) powered by EnduraLife™ Battery Technology for treating patients with heart failure.

In their evaluation, NICE, which provides evidence-based guidance to improve health and social care in the National Health Service (NHS) in the United Kingdom, concluded that the extended battery life observed with Boston Scientific EnduraLifepowered CRT-Ds is likely to reduce the number of avoidable replacement procedures a patient may have to undergo, thereby offering improved outcomes for patients and potential savings to the NHS in England of approximately £6 million in the first five years.

The savings were calculated by modeling the costs associated with early replacement procedures, such as a reduction in hospital admissions, bed days and procurement costs. Fewer replacement procedures also equate to a reduction in associated costs accrued from post-operative complications and infections – both of which also have a measurable impact on morbidity and mortality.

“The NICE guidance reinforces the multi-faceted importance of battery longevity in devices treating patients with heart failure and life-threatening ventricular arrhythmias,” said Dr. Jay Wright, consultant cardiologist, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom. “Additionally, the reduction in replacement procedures and potential savings identified within the guidance could offer longer-term relief to NHS providers who have recently seen an increase in the number of patients requiring further in-hospital treatment.”

The NICE medical technologies advisory committee found that the evidence from 16 independent clinical and economic studies supported a case for adoption and concluded that EnduraLife-powered CRT-Ds have a greater battery capacity and longer battery life compared with other CRT-Ds reviewed.

“Battery life should be a key consideration in cardiac device selection for the millions of patients who rely on them daily,” said Kenneth Stein, M.D., senior vice president and chief medical officer, Global Health Policy and Rhythm Management, Boston Scientific. “We are proud to have our EnduraLife Battery Technology recognized by NICE’s evidence-based review process and available for the benefit of patients and the healthcare system at large.”

EnduraLife Battery Technology, which has nearly two times the usable battery capacity as certain competitive devices[i],[ii] and is packaged in a device up to 18 percent smaller than other CRT-Ds[iii],[iv],[v], was introduced in the company’s line of CRT-Ds in 2008.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.